Clinical trials and tribulations

the MASCOT study

Warren Lenney, Sophie Perry, David Price

Research output: Contribution to journalEditorial

15 Citations (Scopus)

Abstract

The MASCOT study
The protocol required 900 children to use inhaled corticosteroids (ICS) for a 4 week open run-in followed by 48 weeks (double blind, double dummy) taking ICS, ICS plus LABA or ICS plus montelukast. The primary outcome measure was the exacerbation rate. The HTA funded MASCOT research costs. MSD and GlaxoSmithKline (GSK) agreed to supply medication. There was a delay in appointing a trial coordinator to oversee the 13 sites which had readily agreed to participate. The lengthy task of writing the protocol to EU standards (in addition to the original protocol designed for HTA application) was new and baffling to many of us, as was the preparation and submission of the Clinical Trials Authorisation.
Original languageEnglish
Pages (from-to)457-458
Number of pages2
JournalThorax
Volume66
Issue number6
Early online date11 Mar 2011
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Adrenal Cortex Hormones
Clinical Trials
montelukast
Outcome Assessment (Health Care)
Costs and Cost Analysis
Research

Cite this

Clinical trials and tribulations : the MASCOT study. / Lenney, Warren; Perry, Sophie; Price, David.

In: Thorax, Vol. 66, No. 6, 06.2011, p. 457-458.

Research output: Contribution to journalEditorial

Lenney, Warren ; Perry, Sophie ; Price, David. / Clinical trials and tribulations : the MASCOT study. In: Thorax. 2011 ; Vol. 66, No. 6. pp. 457-458.
@article{364d9033ccf645ce9f6966a16235a975,
title = "Clinical trials and tribulations: the MASCOT study",
abstract = "The MASCOT study The protocol required 900 children to use inhaled corticosteroids (ICS) for a 4 week open run-in followed by 48 weeks (double blind, double dummy) taking ICS, ICS plus LABA or ICS plus montelukast. The primary outcome measure was the exacerbation rate. The HTA funded MASCOT research costs. MSD and GlaxoSmithKline (GSK) agreed to supply medication. There was a delay in appointing a trial coordinator to oversee the 13 sites which had readily agreed to participate. The lengthy task of writing the protocol to EU standards (in addition to the original protocol designed for HTA application) was new and baffling to many of us, as was the preparation and submission of the Clinical Trials Authorisation.",
author = "Warren Lenney and Sophie Perry and David Price",
year = "2011",
month = "6",
doi = "10.1136/thx.2010.156885",
language = "English",
volume = "66",
pages = "457--458",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group Ltd",
number = "6",

}

TY - JOUR

T1 - Clinical trials and tribulations

T2 - the MASCOT study

AU - Lenney, Warren

AU - Perry, Sophie

AU - Price, David

PY - 2011/6

Y1 - 2011/6

N2 - The MASCOT study The protocol required 900 children to use inhaled corticosteroids (ICS) for a 4 week open run-in followed by 48 weeks (double blind, double dummy) taking ICS, ICS plus LABA or ICS plus montelukast. The primary outcome measure was the exacerbation rate. The HTA funded MASCOT research costs. MSD and GlaxoSmithKline (GSK) agreed to supply medication. There was a delay in appointing a trial coordinator to oversee the 13 sites which had readily agreed to participate. The lengthy task of writing the protocol to EU standards (in addition to the original protocol designed for HTA application) was new and baffling to many of us, as was the preparation and submission of the Clinical Trials Authorisation.

AB - The MASCOT study The protocol required 900 children to use inhaled corticosteroids (ICS) for a 4 week open run-in followed by 48 weeks (double blind, double dummy) taking ICS, ICS plus LABA or ICS plus montelukast. The primary outcome measure was the exacerbation rate. The HTA funded MASCOT research costs. MSD and GlaxoSmithKline (GSK) agreed to supply medication. There was a delay in appointing a trial coordinator to oversee the 13 sites which had readily agreed to participate. The lengthy task of writing the protocol to EU standards (in addition to the original protocol designed for HTA application) was new and baffling to many of us, as was the preparation and submission of the Clinical Trials Authorisation.

U2 - 10.1136/thx.2010.156885

DO - 10.1136/thx.2010.156885

M3 - Editorial

VL - 66

SP - 457

EP - 458

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 6

ER -